Weekly FDA Roundup: A 14-Warning-Letter Day, a New Medicare Coverage Pathway, and the First Gene Therapy for Deafness, April 18–24, 2026

Quiet week on the calendar. Loud week in the database.

Across April 18–24, the FDA posted 15 warning letters (14 of them on Friday alone), 4 draft guidances, 4 final rules, 5 safety alerts, 5 recalls, and four press releases that reset device reimbursement, gene therapy approvals, and the agency's posture on psychedelic research. We pulled every item, cross-checked the ones that matter, and stripped out the noise. Here is what we would brief a regulatory affairs lead on before Monday.

One Friday, seven CGMP warning letters, one pattern

On April 21, the FDA posted 14 warning letters. Seven of them were CGMP letters: Par Health USA/Endo USA, UCSF Radiopharmaceutical Facility, Apollo Care, RC Outsourcing, Thrive Health and Wellness, New Life Pharma, and Xiamen Kang Zhongyuan Biotechnology. Six involved sterile injectables or sterile compounded drugs. The seventh, Xiamen, is a Chinese finished-pharmaceutical manufacturer cited for insanitary conditions and a separate cough drop recall.

The failure modes repeat:

• Aseptic processing breaking down at the barrier. Par Health and Endo's Rochester, Michigan site was cited for inadequate restricted access barrier systems (RABS), deficient environmental monitoring of ISO 5 areas, dynamic airflow studies that "demonstrated airflow patterns failed to adequately protect the aseptic processing line," and a visual inspection program where personnel could not achieve a 70% probability of detecting critical particulates larger than 150 microns. UCSF was cited for sterility failures involving Bacillus species the firm did not adequately investigate.
• 503B outsourcing facilities running aseptic operations they cannot validate. Apollo Care voluntarily recalled an epidural injection lot for lack of sterility assurance. RC Outsourcing recalled bevacizumab for the same reason. Thrive Health and Wellness was cited for compounding inside unclassified space, in unsterile gloves, repackaging NAD+ and a tirzepatide/B12 combination it called "MEGALean."
• Unapproved GLP-1s dressed up as compounded drugs. New Life Pharma was making injectables with semaglutide and tirzepatide, falsifying its facility registration, failing to list products, and refusing investigators access to parts of the plant during inspection. The FDA's response is unusually direct: the agency "strongly advised the firm not to restart operations."
• Foreign-manufacturer CGMP and data integrity. Xiamen Kang Zhongyuan Biotechnology, a Fujian Province manufacturer, was cited for preparing, packing, or holding drug products under insanitary conditions. The firm initiated a Class II recall on March 20 covering 15 mentholated cough drop products across five brands (Exchange Select, Caring Mill, Discount Drug Mart, MGC Health, QC Quality Choice). Different product class from the sterile cluster, but the regulatory mechanism is the same.

What this tells us: the FDA's enforcement posture on sterile drug manufacturing is now load-bearing. This is the weekly cadence now, 5 to 7 letters naming the same handful of failure modes. If you run a 503B, a radiopharmacy, or an aseptic fill line, your inspection plan is already obsolete if it was written before March.

RAPID coverage pathway: same-day Medicare coverage proposals for Breakthrough Devices

On April 23, CMS and FDA jointly announced the Regulatory Alignment for Predictable and Immediate Device (RAPID) coverage pathway. The mechanics matter more than the branding.

Under RAPID, CMS will issue a proposed National Coverage Determination on the same day an eligible Breakthrough Device receives FDA market authorization. That triggers the statutory 30-day comment period immediately, not after the historical year-plus CMS queue. The intended end-state is national Medicare coverage roughly two months after authorization, versus the current twelve-plus.

Eligibility has two gates. The device must be a Class II Breakthrough participating in FDA's Total Product Life Cycle Advisory Program (TAP), or a Class III Breakthrough regardless of TAP status. It must also be the subject of an IDE study that enrolls Medicare beneficiaries and measures clinical outcomes agreed by both FDA and CMS up front.

Two second-order effects worth tracking:

1. TCET is paused for new entrants. CMS explicitly put the Transitional Coverage for Emerging Technologies program on hold for new candidates to focus resources on RAPID. Device sponsors mid-stream in TCET need to confirm status before assuming continuity.
2. Your IDE design is now a coverage document. Any sponsor targeting Medicare at launch needs to treat endpoint selection, study population, and real-world follow-up as both an FDA and CMS conversation from the start. The cost of designing an IDE the agency accepts but CMS does not is now a year of lost coverage.

Public comment on the pathway runs 60 days from the Federal Register publication of the proposed rule.

First gene therapy for genetic hearing loss, approved in 61 days

On April 23, the FDA granted accelerated approval to Otarmeni (lunsotogene parvec-cwha), Regeneron's dual-vector AAV gene therapy for OTOF-associated severe-to-profound sensorineural hearing loss. This is the first approved gene therapy for any form of hereditary deafness. It is also the sixth approval under the Commissioner's National Priority Voucher (CNPV) pilot, and the first gene therapy approved under the program. The BLA cleared in 61 days. Orforglipron cleared the same lane first at 50 days in March, as the first new molecular entity under CNPV.

The headline numbers from the trial: 80% of treated patients achieved at least some significant hearing restoration; 42% ended up with normal hearing, including the ability to hear whispers. Regeneron is providing the therapy for free in the U.S., a pricing posture rare enough to note.

Two regulatory signals sit underneath the press release:

• CNPV is no longer experimental. Six approvals in two months, including a 50-day NME and a 61-day gene therapy, mean the voucher program is becoming the FDA's default priority lane. The agency scheduled a June 4 public meeting on the program's future. Sponsors with pipeline candidates that might plausibly qualify should have a position by then. Comment period closes June 29.
• Postmarketing commitments are real. Continued approval is conditioned on Regeneron verifying long-term durability of efficacy. That lines up with the April 24 Federal Register notice announcing the annual report on drug and biologics firms' performance on postmarketing requirements. The agency is cleaning that queue up in public.

Class I device alerts: two component-defect cascades in three weeks

Five device safety alerts hit the feed this week. All worth surfacing to clinical teams on Monday.

• Tandem Mobi insulin pumps, Class I. Software versions 7.6.0.1, 7.6.0.3, and 7.7.0.1 can incorrectly detect a motor failure, trigger "Malfunction 12," stop insulin delivery, and disrupt CGM communication. Four serious injuries reported (as of November 4, 2025). No deaths. The fix is a software update to version 7.9.0.2.
• Integra LifeSciences Codman Disposable Perforators, Class I. An inadequate ultrasonic weld ("proud weld") on the outer sleeve can cause the device to disassemble before, during, or after craniotomy. Ten reported injuries include device fragments lodged in the patient's skull, dural injury, and cerebral injury. Roughly 170,000 perforators recalled. No deaths. Affected kits need to be quarantined immediately.
• Early alert on Aligned Medical Solutions convenience kits. Kits containing previously-recalled Medline Namic Angiographic Control Syringes. Rotating adaptors can unwind during use, risking air embolism, blood loss, or infection. Either remove the syringes from the kit or apply prominent warning labels before the kit is used.
• Early alert on Arrow International dialysis catheter kits. Kits containing Merit Medical 16F Splittable Sheath Introducers, the same component the FDA flagged Class I last week. This is the second component-defect cascade in three weeks. Two weeks ago the Medline Namic RA Syringe defect forced Early Alerts at Medical Action Industries and Owens & Minor for kits that contained it. This week Arrow International is doing the same with Merit Medical's component.
• Early alert on Omnicell automated compounding system. Omnicell flagged an automation issue with its compounding system on April 24. Same week the agency posted seven CGMP letters against compounders. The connection is circumstantial. The timing is worth noting if you operate an automated compounding line.

Two patterns to extract. First, software- and assembly-defect recalls where the manufacturer knew the failure mode before FDA action. Tandem and Integra both fit. Second, the component-defect cascade. When a single OEM component fails, every kit-maker downstream has to pull product. We have now seen two of these inside three weeks (Medline Namic RA Syringe, Merit Medical Splittable Sheath). If you build kits from third-party components, your supplier qualification audit is the most important document in your quality file this month.

Nicotine pouch flavor enforcement continues to cluster

Three of the 14 warning letters on April 21 went to online retailers selling unauthorized Zyn pouch variants: shopcalismokes.com, vapepengood.com, and nicoprof.com. The cited products include "Cool Skittle," "Fizzy Cola," "Icy Blackcurrant XX Strong," "Red Fruits," and "Cool Blueberry." The through-line is the lack of premarket authorization. The flavor profile is incidental, but the product names are doing work for the Center for Tobacco Products' retail-enforcement narrative. Daily Manufacturing Solutions Inc. picked up a similar tobacco-product letter on April 23.

A separate April 23 Federal Register notice finalized 18 additions to the list of Harmful and Potentially Harmful Constituents in tobacco products (bringing the list to 111 substances), and opened comment on three more: pulegone, furfuryl alcohol, and methyl eugenol. Comments close May 26. Any company filing PMTAs should align their reporting with the amended HPHC list before the next submission.

Three draft guidances opened comment periods

If you do not track Federal Register notices, here is what matters:

• Establishing Impurity Specifications for Antibiotics (CDER). Applies to NDAs, ANDAs, type II DMFs, and OTC antibiotic monographs. Comment closes June 22.
• Compliance Policy on Certain NIOSH-Approved Air-Purifying Respirators (CDRH). Covers surgical N95s, PAPRs, FFRs, and respirators for use by the general public in public health emergencies. Comment closes June 22.
• CVM GFI #91 (VICH GL8 R1) on stability testing for veterinary medicated premixes. Comment closes June 15.

If any of these touch your product, draft comments now. The agency has been more responsive to substantive industry input under the current guidance cycle than it was a year ago.

Psychedelic therapy: faster lane, new vouchers

Following the executive order on mental health, the FDA announced priority review vouchers tied to psilocybin and methylone research, cleared an IND for noribogaine hydrochloride for alcohol use disorder, and said final guidance on trial design for serotonin-2A agonists is coming. Sponsors in this space should read the announcement carefully. The agency is making clear that the regulatory pathway for psychedelics is no longer hypothetical.

Animal-testing reduction goals: year one, cleared

The FDA reported completing its year-one 2025 roadmap on reducing animal testing in drug development. Key deliverables: draft guidance reducing nonhuman primate testing for monoclonal antibodies, updated guidance on moving away from horseshoe crab–derived endotoxin testing, and qualification of the first AI-based drug development tool. For biologics and device sponsors, this is the quietly consequential part. "New approach methodologies" (NAMs) are now the default position in the agency's language.

The one-line take

The FDA is running two plays at once. The agency is accelerating priority programs across devices and gene therapy, while tightening the squeeze on sterile drug manufacturing until the quality baseline catches up. If you are a sponsor, your IDE is now a coverage document. If you are a compounder, your EM trend report is your inspection defense. If you build kits from third-party components, your supplier audit is the document that saves you this month.

---

We monitor the FDA daily for your products. If you manufacture, import, compound, or sell FDA-regulated goods, Policy Canary tells you which of these items actually touches your SKUs, before your lawyer does.